Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)

NCT04218084 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04218084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04218084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
November 11, 2020
Completion date
November 6, 2024
Enrollment
236 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease